E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi-aventis

By E. J. Mckay, PRNE
Sunday, October 31, 2010

PARIS, November 1, 2010 - Sanofi-aventis (EURONEXT: SAN; NYSE: SNY) and BMP Sunstone Corporation
(Nasdaq: BJGP) announced today that they have signed a definitive agreement
under which Sanofi-aventis is to acquire all outstanding shares of BMP
Sunstone for USD10 per share, for a total purchase price of USD520.6 million
on a fully diluted basis. This price per share represents a 30% premium on
BMP's October 27, 2010 closing share price. E. J. McKay and Stephens Inc.
acted as BMP Sunstone's financial advisors, while Morgan Stanley represented
Sanofi-aventis.

The acquisition of BMP Sunstone, which holds many leading Chinese
pediatric and hygienic brands, will provide Sanofi-aventis with significant
growth opportunities in the Chinese healthcare market, and specifically in
its two largest categories: Vitamin & Minerals Supplements and Cough & Cold.

This transaction marks the largest Chinese pharmaceutical deal of the
year, and is a prime example of the synergies and value that cross-border
transactions can create. E. J. McKay CEO James Z. Li stated, "We are very
pleased with the positive outcome. This acquisition will significantly boost
Sanofi-aventis' China presence, meanwhile creating significant value for BMP
Sunstone's shareholders. It is representative of the selectivity of our
clients and the value and expertise E. J. McKay provides."

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Reporting revenue of EUR29.3 billion in 2009, the company maintains
over 100,000 employees in over 100 countries.

About BMP Sunstone

BMP Sunstone Corporation is a specialty pharmaceutical company that is
building a proprietary portfolio of branded pharmaceutical and healthcare
products in China. Through Sunstone, the Company manufactures leading
pediatric and women's health products sold in pharmacies throughout the
country. The Company also markets a portfolio of products under exclusive
multi-year licenses into China, as well as provides pharmaceutical
distribution.

About E. J. McKay

E. J. McKay is a Shanghai based investment banking group specialized in
structuring complex cross-border mergers & acquisitions and merchant banking
transactions. Through its offices and strategic partnerships, the firm is
present in thirty major financial centers around the world. E. J. McKay has a
dedicated focus on China, and advises transactions both inbound and outbound,
representing clients both local and multinational.

    Contact:

    www.ejmckay.com
    www.ejmckay.net
    Natalie Hsiao
    Tel: +86-21-5109-6266
    Email: natalie.hsiao@ejmckay.com

Natalie Hsiao, +86-21-5109-6266, or natalie.hsiao at ejmckay.com

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :